 Community-acquired Pneumonia CAP remains a leading cause of death in both developing and developed countries. In the choice of antibacterial agents used to treat CAP, fluoroquinolones have received considerable attention because of their wide spectrum of bactericidal activity. TG-873870 Nemonoxacin, a non-fluorinated quinolone NFQ, is a selective bacterial topoisomerase inhibitor. 